Journal Information
Vol. 26. Issue 2.
Pages 105-107 (March - April 2020)
Share
Share
Download PDF
More article options
Visits
...
Vol. 26. Issue 2.
Pages 105-107 (March - April 2020)
Case report
DOI: 10.1016/j.pulmoe.2019.05.005
Open Access
Autonomy and dyspnea in palliative care: A case report
Visits
...
M. Martinsa,
Corresponding author
monicateixeiramartins@gmail.com

Corresponding author.
, E. Campôab, M. Ferreirac, P. Reis-Pinac,d
a Unidade de Saúde Familiar do Dafundo, Lisboa, Portugal
b Serviço de Oncologia Médica, Centro Hospitalar Universitário do Algarve, Faro, Portugal
c Unidade de Cuidados Paliativos São Bento Menni, Casa de Saúde da Idanha, Belas, Sintra, Portugal
d Centro de Bioética, Faculdade de Medicina, Universidade de Lisboa, Portugal
Article information
Full Text
Bibliography
Download PDF
Statistics
Full Text
Introduction

Dyspnea is a complex and subjective experience, its intensity is wholly determined by the patient's sensation and how it is perceived depends on previous beliefs, emotions, values and experiences.1,2 Several measures are employed to alleviate dyspnea, which must be acceptable to the patient. Thus, therapeutic adherence is promoted, and a good symptomatic control is achieved, as illustrated in the present case.

Case report

M.S., female, 61 years old, divorced, retired, with asthma-chronic obstructive pulmonary disease overlap syndrome (ACOS) diagnosed four years ago, and still worsening, currently under noninvasive ventilation (NIV) and long-term oxygen therapy (LTOT). She has a history of hypertensive heart disease and anxiety disorder. She is an ex-smoker (40 Units Year Package).

She was followed in outpatients clinics in General and Family Medicine and Pulmonology, suffering from irreversible respiratory insufficiency, which was potentially difficult to control due to therapeutic failure. She had had multiple admissions to acute hospitals due to the exacerbation of her pathology, ending up being referred to and admitted into a Palliative Care Unit (PCU) for symptomatic control of dyspnea and fatigue. On admission she presented with a grade 4 dyspnea (Modified Dyspnea Scale Medical Research Council) and a performance status of 4 (Eastern Cooperative Oncology Group). Her Palliative Performance Scale was 50–60%. She was prescribed montelukast 10mg id, aminophylline 225mg bid, tiotropium bromide 1.25mcg 2 id inhalations, fluticasone/salmeterol 250/25mcg 2 bid inhalations, salbutamol 100mcg PRN inhalations, lisinopril 5mg id, omeprazole 20mg id, and hydroxyzine 25mg bid.

After her admission to the PCU, therapeutic adjustments were made according to her symptoms. Prolonged-release morphine was prescribed (10mg bid) after proper titration with immediate-release morphine (5mg PRN), butylscopolamine 20mg tid, prednisolone 10mg id and laxatives (macrogol 13.7g bid and sennosides 7.5mg bid). Due to the patient's refusal to keep on LTOT and NIV, even after multiple adjustments, they were progressively reduced and suspended; yet symptomatic control was not compromised. Likewise, due to the patient's non-compliance with inhalation therapy, without the symptomatic relief expected, and considering her wishes, it was suspended. She used a hand fan, but because there was an air conditioner unit in the room, she preferred to turn it on. Pulse oximetry, when measured, was more than 90%. A physical rehabilitation plan was implemented with an adaptative training program.

Because she complained of pruritus, an opioid-related side-effect, morphine dose was initially reduced, and an opioid rotation to tapentadol was done.

At follow up evaluation after three weeks, through daily clinical evaluation, symptoms have been well controlled: dyspnea and fatigue are mild (self-assessment). She is fully motivated to her rehabilitation plan and shows good compliance with it.

Currently her regular medications are: escitalopram 10mg id, pantoprazole 20mg id, aminophylline 225mg bid, lorazepam 1mg id, tapentadol 50mg bid, prednisolone 5mg id and bisacodyl 5mg id.

Discussion

Patients diagnosed with ACOS are over 40 years old (15–55% of them are over 50 years old) and experience frequent exacerbations, showing a quick decline in lung function and high mortality.3

Mrs MS frequent exacerbations and worsening of her clinical condition were considered to be due to lack of motivation to adhering to the therapeutic regimen and other inherent factors. In fact, perhaps Mrs MS did not understand the therapeutic plan, or the medications she was prescribed were not adjusted to her needs. Moreover, a lack of an effective doctor–patience communication may have led to non-compliance and therapeutic failure.

The principle of autonomy respects the ability of an individual to self-determination, allowing or enabling patients to make their own decisions about any medical interventions.4 Consequently, the doctor-patient relationship has moved from a paternalistic and disease-centered model to a person-centered care model. Informed consent is essential to the latter process and the patient has the right to refuse any intervention that is proposed.5

In Portugal, according to Decree-Law no. 25/2012 (July 16th), a legally aged and capable person, who is not prohibited or disabled by psychiatric abnormality, can declare and specify the type(s) of healthcare he/she wishes to receive, or not, in case of – for any reason – he/she finds him/herself unable to express his/her preferences, personally and autonomously, in the form of advance directives, namely in the form of a living will. This document has to record provisions relating to healthcare for serious or irreversible illnesses at an advanced stage, including appropriate symptomatic therapy.

Mrs MS had neither interest nor the will to keep to a therapeutic plan that included inhalers, masks or any other of the respiratory accessories that were proposed, which is the reason why she did not comply with them at all. With Mrs MS preferences and in her best interest in mind, pharmacological adjustments were made to her plan of care, leading to good symptomatic control and excellent therapeutic adherence.

In palliative care (PC), in advanced respiratory diseases, symptomatic relief of dyspnea is of capital importance. Pharmacologic palliation of dyspnea involves the use of opioids, oxygen, and/or benzodiazepines.6 Systematic opioids therapy are the mainstay of palliative pharmacologic management of severe dyspnea and their effectiveness has been demonstrated in numerous clinical trials.6–8 However, a recent systematic review suggests that some of the evidence that shows benefit from their use is of low quality.9 In many studies that have used opioids for the relief of dyspnea, it has been stated that the initial dose for a specific patient is to be defined according to the intensity of dyspnea reported, preferably through self-assessment; and after the titration phase the dose should be readjusted.10,11 The ideal therapeutic dose is the minimum dose that promotes, from the patient's perspective, both good symptomatic control and tolerable/acceptable side effects. The opioid prescription should happen according to the patient's functional status and in agreement with previous opioid use.

Often, anxiety is a factor to take in consideration, as it contributes to symptomatic exacerbations, therefore therapy should be adjusted accordingly. The effect of morphine and its analogs is amplified when used in combination with benzodiazepines.1,12

Mrs MS's weaning from oxygen therapy may be considered controversial – since this therapy is often used in the end-of-life as a first-line strategy in the management of dyspnea. However, Mrs MS had demanded the weaning to proceed. The indications for oxygen therapy in advanced disease are partial, with no evidence of improved survival.1

The use of a low-dose systemic corticosteroid treatment has been advocated. In PC, the prescription of corticosteroids in a low-dose/short duration scheme has been described, without great evidence about its benefits. Corticosteroids are pluripotent drugs that can be used in pain control (as adjuvant analgesics), nausea/vomit control, appetite and lethargy management (syndrome of anorexia-cachexia), etc.13

NVI is an extremely important measure, usually well accepted by patients, unlike what happened to this patient probably due to her anxiety.14 It would be considered effective if it improves dyspnea without causing other troubling consequences.15 Other non-pharmacological interventions are also used to control dyspnea, such as appropriate room environment, adequate body positioning, breathing, physiotherapy techniques and acupuncture.16,17 Several studies have demonstrated inadequate symptom management in patients with advanced respiratory disease, the discomfort of physicians in prescribing opioids is one of the contributors to this.18 Although there is a growing awareness about the need for PC in end-stage non-neoplastic respiratory diseases, there are some accessibility and clinical issues that prevent patients being referred to PC services. Sometimes, physicians’ reluctance and/or difficulties to define “a palliative care status” may contribute to that.19

The present case reflects: (a) the respect for each patient's preferences and autonomy in clinical practice; (b) the prescription of less common treatments for dyspnea control, such as opioids, corticosteroids and benzodiazepines in PC; (c) the importance of shared decision-making in clinical management of patients with advanced disease.

Conflicts of interest

The author has no conflicts of interest to declare.

References
[1]
M. Feio.
Dispneia.
Manual de Cuidados Paliativos, 3rd ed., pp. 219-229
[2]
L. Pisani, N.S. Hill, A.M.G. Pacilli, M. Polastri, S. Nava.
Management of dyspnea in the terminally ill.
[3]
GINA/GOLD.
Diagnosis of diseases of chronic airflow limitation: asthma, COPD and asthma-COPD overlap syndrome (ACOS). A joint project of GINA and GOLD.
(2015),
[4]
J.O. Ascensão.
Almedina, (2009), pp. 151-155
[5]
A.G.D. Pereira.
O Consentimento Informado na Relação Medico-Paciente: estudo de direito civil.
Coimbra Editora, (2004), pp. 33-35
[6]
A.H. Kamal, J.M. Maguire, J.L. Wheeler, D.C. Currow, A.P. Abernethy.
Dyspnea review for the palliative care professional: treatment goals and therapeutic options.
J Palliat Med, 15 (2012), pp. 106-114
[7]
A.L. Jennings, A.N. Davies, J.P. Higgins, K. Broadley.
Opioids for the palliation of breathlessness in terminal illness.
Cochrane Database System Rev, (2001),
[8]
P.N. Lanken, P.B. Terry, M. Horace, et al.
An official American Thoracic Society clinical policy statement: palliative care for patients with respiratory diseases and critical illness.
Am J Respir Crit Care Med, 177 (2008), pp. 912-927
[9]
H. Barnes, J. McDonald, N. Smallwood, R. Manser.
Opioids for the palliation of refractory breathlessness in adults with advanced disease and terminal illness.
Cochrane Database Syst Rev, 3 (2016), pp. CD011008
[10]
K.E. Clemens, et al.
Is there a higher risk of respiratory depression in opioid-naïve palliative care patients during symptomatic therapy of dyspnea with strong opioids?.
[11]
R. Viola, et al.
The management of dyspnea in cancer patients: a systematic review.
Support Care Cancer, 16 (2008), pp. 329-337
[12]
K.E. Clemens, E. Klaschik.
Dyspnoea associated with anxiety – symptomatic therapy with opioids in combination with lorazepam and its effect on ventilation in palliative care patients.
Support Care Cancer, 19 (2011), pp. 2027-2033
[13]
A. Denton, J. Shaw.
Corticosteroid prescribing in palliative care settings: a retrospective analysis in New Zealand.
BMC Pall Care, 13 (2014), pp. 7
[14]
S. Nava, M. Ferrer, A. Esquinas, R. Scala, P. Groff, R. Cosentini, et al.
Palliative use of non-invasive ventilation in end-of-life patients with solid tumours: a randomised feasibility trial.
Lancet Oncol, 14 (2013), pp. 219-227
[15]
B. Rochwerg, L. Brochard, M.W. Elliott, D. Hess, N.S. Hill, S. Nava, et al.
Official ERS/ATS clinical practice guidelines: noninvasive ventilation for acute respiratory failure.
Eur Respir J, 50 (2017), pp. 1602426
[16]
C. Bausewein, S. Booth, M. Bysels, I. Higginson.
Nonpharmacologic interventions for breathlessness in advanced stages of malignant and nonmalignant diseases.
Cochrane Database System Rev, 2 (2008), pp. CD005623
[17]
A randomized, placebo-controlled trial of acupuncture in patients with chronic obstructive pulmonary disease (COPD): the COPD-Acupuncture Trial (CAT)..
|Chronic Obstructive Pulmonary Disease|JAMA Internal Medicine|JAMA Network, (2019),
[18]
J. Young, M. Donahue, M. Farquhar, C. Simpson, G. Rocker.
Using opioids to treat dyspnea in advanced COPD.
Can Fam Physician, 58 (2012), pp. e401-e407
[19]
P. Pamplona, C. Bárbara.
Cuidados Paliativos e Insuficiência Respiratória Crónica.
Manual de Cuidados Paliativos, 3rd ed., pp. 447-465
Copyright © 2019. Sociedade Portuguesa de Pneumologia
Pulmonology

Subscribe to our newsletter

Article options
Tools

Are you a health professional able to prescribe or dispense drugs?

Cookies policy
To improve our services and products, we use cookies (own or third parties authorized) to show advertising related to client preferences through the analyses of navigation customer behavior. Continuing navigation will be considered as acceptance of this use. You can change the settings or obtain more information by clicking here.